

Sun-Ranbaxy deal: CCI public scrutiny ends

NEW DELHI: The Competition Commission of India's deadline for public comments on the \$4 billion Sun-Ranbaxy deal, ended Wednesday. This is also the first deal where the CCI ordered a public scrutiny as it opined that it affect competition.

PTI

Gover.